439 related articles for article (PubMed ID: 27001944)
21. Evaluation of interleukin-6 and its soluble receptor components sIL-6R and sgp130 as markers of inflammation in inflammatory bowel diseases.
Nikolaus S; Waetzig GH; Butzin S; Ziolkiewicz M; Al-Massad N; Thieme F; Lövgren U; Rasmussen BB; Reinheimer TM; Seegert D; Rosenstiel P; Szymczak S; Schreiber S
Int J Colorectal Dis; 2018 Jul; 33(7):927-936. PubMed ID: 29748708
[TBL] [Abstract][Full Text] [Related]
22. Plasma intestinal fatty acid-binding protein fails to predict endoscopic disease activity in inflammatory bowel disease patients.
Bodelier AG; Pierik MJ; Lenaerts K; de Boer E; Olde Damink SW; Hameeteman WM; Masclee AA; Jonkers DM
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):807-13. PubMed ID: 26919325
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor-alpha serum level in assessment of disease activity in inflammatory bowel diseases.
Avdagić N; Babić N; Šeremet M; Delić-Šarac M; Drače Z; Denjalić A; Nakaš-Ićindić E
Med Glas (Zenica); 2013 Aug; 10(2):211-6. PubMed ID: 23892833
[TBL] [Abstract][Full Text] [Related]
24. Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activity.
Oikonomou KA; Kapsoritakis AN; Theodoridou C; Karangelis D; Germenis A; Stefanidis I; Potamianos SP
J Gastroenterol; 2012 May; 47(5):519-30. PubMed ID: 22200942
[TBL] [Abstract][Full Text] [Related]
25. Enhanced formation of advanced oxidation protein products in IBD.
Krzystek-Korpacka M; Neubauer K; Berdowska I; Boehm D; Zielinski B; Petryszyn P; Terlecki G; Paradowski L; Gamian A
Inflamm Bowel Dis; 2008 Jun; 14(6):794-802. PubMed ID: 18213700
[TBL] [Abstract][Full Text] [Related]
26. Correlation of serum-soluble triggering receptor expressed on myeloid cells-1 with clinical disease activity in inflammatory bowel disease.
Park JJ; Cheon JH; Kim BY; Kim DH; Kim ES; Kim TI; Lee KR; Kim WH
Dig Dis Sci; 2009 Jul; 54(7):1525-31. PubMed ID: 18975078
[TBL] [Abstract][Full Text] [Related]
27. Plasma Extracellular Vesicle LncRNA H19 as a Potential Diagnostic Biomarker for Inflammatory Bowel Diseases.
Heydari R; Fayazzadeh S; Shahrokh S; Shekari F; Farsad F; Meyfour A
Inflamm Bowel Dis; 2024 May; 30(5):795-807. PubMed ID: 37855715
[TBL] [Abstract][Full Text] [Related]
28. CD8
Dai SX; Gu HX; Lin QY; Huang SZ; Xing TS; Zhang QF; Wu G; Chen MH; Tan WE; Jian HJ; Zheng ZW; Zhong T; Zhang MH; Cheng XF; Huang P; Liao GJ; Sha WH
Clin Res Hepatol Gastroenterol; 2017 Dec; 41(6):693-702. PubMed ID: 28502591
[TBL] [Abstract][Full Text] [Related]
29. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease (IBD).
Kucharzik T; Stoll R; Lügering N; Domschke W
Clin Exp Immunol; 1995 Jun; 100(3):452-6. PubMed ID: 7774055
[TBL] [Abstract][Full Text] [Related]
30. The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.
Lakatos G; Hritz I; Varga MZ; Juhász M; Miheller P; Cierny G; Tulassay Z; Herszényi L
Dig Dis; 2012; 30(3):289-95. PubMed ID: 22722554
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of serum neutrophil gelatinase-associated lipocalin (NGAL), asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) levels, and their relations with disease type and activity in inflammatory bowel diseases.
Korkmaz H; Asıl M; Temel T; Öztürk B; Kebapçılar L
Turk J Med Sci; 2021 Oct; 51(5):2403-2412. PubMed ID: 33984894
[TBL] [Abstract][Full Text] [Related]
32. Level of interleukin 17 in inflammatory bowel disease and its relation with disease activity.
Menesy A; Hammad M; Aref S; Abozeid FAM
BMC Gastroenterol; 2024 Apr; 24(1):135. PubMed ID: 38622545
[TBL] [Abstract][Full Text] [Related]
33. [Inflammatory bowel disease in children--an analysis of the clinical symptoms and selected biochemical parameters].
Landowski P; Liberek A; Szlagatys-Sidorkiewicz A; Radys W; Brodzicki J; Szarszewski A; Marek A; Łuczak G; Kamińska B
Med Wieku Rozwoj; 2007; 11(4):401-7. PubMed ID: 18605192
[TBL] [Abstract][Full Text] [Related]
34. Increased circulating circular RNA_103516 is a novel biomarker for inflammatory bowel disease in adult patients.
Ye YL; Yin J; Hu T; Zhang LP; Wu LY; Pang Z
World J Gastroenterol; 2019 Nov; 25(41):6273-6288. PubMed ID: 31749597
[TBL] [Abstract][Full Text] [Related]
35. Serum procalcitonin differentiates inflammatory bowel disease and self-limited colitis.
Herrlinger KR; Dittmann R; Weitz G; Wehkamp J; Ludwig D; Schwab M; Stange EF; Fellermann K
Inflamm Bowel Dis; 2004 May; 10(3):229-33. PubMed ID: 15290916
[TBL] [Abstract][Full Text] [Related]
36. Association between enhanced soluble CD40 ligand and prothrombotic state in inflammatory bowel disease.
Koutroubakis IE; Theodoropoulou A; Xidakis C; Sfiridaki A; Notas G; Kolios G; Kouroumalis EA
Eur J Gastroenterol Hepatol; 2004 Nov; 16(11):1147-52. PubMed ID: 15489574
[TBL] [Abstract][Full Text] [Related]
37. Serum interleukin-6 is related to disease activity but not disease specificity in inflammatory bowel disease.
Holtkamp W; Stollberg T; Reis HE
J Clin Gastroenterol; 1995 Mar; 20(2):123-6. PubMed ID: 7769191
[TBL] [Abstract][Full Text] [Related]
38. B Cell-Activating Factor as a New Potential Marker in Inflammatory Bowel Disease.
Zhang P; Liu X; Guo A; Xiong J; Fu Y; Zou K
Dig Dis Sci; 2016 Sep; 61(9):2608-18. PubMed ID: 27056038
[TBL] [Abstract][Full Text] [Related]
39. Is ischemia modified albumin a disease activity marker for inflammatory bowel diseases?
Kaplan M; Yuksel M; Ates I; Kilic ZM; Kilic H; Kuzu UB; Kayacetin E
J Gastroenterol Hepatol; 2016 Jun; 31(6):1120-5. PubMed ID: 26642816
[TBL] [Abstract][Full Text] [Related]
40. [Expression of elafin in peripheral blood in inflammatory bowel disease patients and its clinical significance].
Zhang W; Teng GG; Tian Y; Wang HH
Zhonghua Yi Xue Za Zhi; 2016 Apr; 96(14):1120-3. PubMed ID: 27095781
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
